Class summary at a glance.

Every drug in the Vasopressin Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $24.1Mcombined across class
Total Rx claims: 294K69K unique beneficiaries
Generic mfrs (active): 13across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Desmopressin

Brand: DDAVP · 294K Part D claims (CY24) · 69K beneficiaries · First FDA approval: 1984-05-01

13 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC$0.237

→

Avg plan cost$9.48

Part D spend $24.1M 40× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.